TrialRMD open2021

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.

Iain B McInnes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.